Welcome to our dedicated page for Qiagen SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Qiagen鈥檚 SEC filings can read like a molecular biology textbook鈥攄ense with PCR acronyms, regulatory trial data and segment splits between consumables and instruments. Whether you are comparing QuantiFERON sales curves or tracking how new QIAstat-Dx cartridges flow through revenue, hunting for the right numbers across a 300-page Form 20-F or a mid-quarter 6-K is a genuine challenge.
Stock Titan decodes those complexities in seconds. Our AI-powered summaries highlight what matters in each document鈥攇ross margin shifts inside the annual report 20-F (think of it as Qiagen鈥檚 annual report 10-K simplified), pipeline milestones hidden in a 6-K material update, and every Qiagen insider trading Form 4 transaction the moment it hits EDGAR. Want to monitor Qiagen quarterly earnings report 10-Q filing equivalents, dig into executive compensation in the proxy statement, or follow Qiagen 8-K material events explained? Our real-time alerts and plain-language explanations do the heavy lifting so you don鈥檛 have to translate biotech jargon.
That insight turns raw data into practical decisions:
- Flag unusual Qiagen Form 4 insider transactions in real-time before material announcements
- Compare consumables versus instrument revenue across regions in seconds
- Trace regulatory approvals, IP litigation or M&A activity through every filing
Understanding Qiagen SEC documents with AI means you can focus on strategy, not page-count. From earnings report filing analysis to executive stock transactions Form 4, every disclosure is distilled into clear, searchable insight鈥攗pdated the instant Qiagen presses 鈥渟ubmit.鈥�
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.
QGEN Form 144 summary: This filing notifies a proposed sale under Rule 144 of 31,423 common shares by an insider brokered through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $1,546,256.70 and an approximate sale date of 08/15/2025. The shares were acquired as performance shares on 02/28/2025. The filing also reports sales by the same person during the prior three months totaling 68,577 common shares for gross proceeds of $3,336,720.01 across trades on 08/13鈥�08/14/2025. The filer certifies no undisclosed material adverse information.
Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.
Qiagen N.V. (QGEN) disclosure shows a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,456,435.00. With 216,556,000 shares outstanding, the proposed block represents roughly 0.023% of the company. The shares were received as performance shares on 02/21/2023 (15,378 shares) and 02/28/2023 (34,622 shares). The filing reports 鈥淣othing to Report鈥� for sales in the past three months and includes the seller's attestation that they are not aware of undisclosed material adverse information.
Wellington Management entities disclosed beneficial ownership of 26,023,940 shares of Qiagen N.V. (CUSIP N72482206), equal to 11.95% of the outstanding common stock. The filing shows shared voting power of 20,289,753 shares and shared dispositive power of 26,023,940 shares. The reporting persons are multiple Wellington entities, some classified as holding companies and one as an investment adviser, and the securities are owned of record by clients of Wellington investment advisers. The statement affirms the holdings are held in the ordinary course of business and not for the purpose of changing or influencing issuer control.
FAQ
What is the current stock price of Qiagen (QGEN)?
What is the market cap of Qiagen (QGEN)?
